Upcoming loss-of-exclusivity events for branded drugs, ranked by Medicare Part D spending.
Orange Book data: Jul 1, 2026 · Medicare spending: 2023 data (CMS 18–24 month lag)
$16.7B
Revenue at risk (12mo) — 2023 data
19
Expiring in 90 days
91
Expiring in 12 months
557
With Para IV filings
Highest Revenue at Risk
| Drug | Patents | LOE Date | Medicare Spend (2023) ↓ |
|---|---|---|---|
| ELIQUISN202155 | 2 | Apr 17, 2028(1.8yr) | $18.3B |
| JANUVIAN021995 | 1 | May 24, 2027(11mo) | $4.1B |
| REVLIMIDN021880 | 2 | Mar 8, 2028(1.7yr) | $3.9B |
| ENTRESTON207620 | 6 | Nov 27, 2027(1.4yr) | $3.4B |
| XTANDIN203415 | 4 | Nov 17, 2026(5mo) | $2.6B |
| OFEVN205832 | 4 | Sep 6, 2026(2mo) | $1.8B |
| VYNDAMAXN212161 | 3 | Dec 19, 2026(6mo) | $1.3B |
| CALQUENCEN210259 | 9 | Nov 24, 2026(5mo) | $1.3B |
| XIFAXANN021361 | 19 | Sep 2, 2027(1.2yr) | $1.1B |
| JANUMETN022044 | 2 | May 24, 2027(11mo) | $799M |
| SPIRIVAN021395 | 1 | Jul 19, 2026(1mo) | $783M |
| VASCEPAN202057 | 61 | Sep 25, 2027(1.2yr) | $764M |
| ABILIFYN021436 | 2 | Mar 2, 2027(8mo) | $658M |
| REXULTIN205422 | 5 | May 9, 2028(1.9yr) | $630M |
| SPRYCELN021986 | 1 | Sep 28, 2026(3mo) | $510M |
| INCRUSE ELLIPTAN205382 | 1 | Dec 18, 2027(1.5yr) | $456M |
| LATUDAN200603 | 6 | Nov 26, 2026(5mo) | $455M |
| TYVASO DPIN214324 | 6 | May 14, 2027(11mo) | $437M |
| STIOLTO RESPIMATN206756 | 1 | Jan 19, 2027(7mo) | $432M |
| JANUMET XRN202270 | 1 | May 24, 2027(11mo) | $392M |
| ROWASAN019618 | 1 | Jul 24, 2027(1.1yr) | $363M |
| INVOKANAN204042 | 3 | Jun 3, 2028(1.9yr) | $357M |
| XELJANZN203214 | 1 | Feb 21, 2028(1.6yr) | $280M |
| TYMLOSN208743 | 9 | Oct 3, 2027(1.3yr) | $198M |
| ORENITRAMN203496 | 7 | Oct 18, 2026(4mo) | $183M |
| NUEDEXTAN021879 | 1 | Aug 13, 2026(1mo) | $181M |
| BELBUCAN207932 | 3 | Jul 23, 2027(1.1yr) | $150M |
| PREZISTAN021976 | 1 | Jun 26, 2027(12mo) | $133M |
| DIFICIDN201699 | 4 | Sep 4, 2027(1.2yr) | $127M |
| VYNDAQELN211996 | 2 | Dec 19, 2026(6mo) | $118M |
| DOPTELETN210238 | 1 | Jul 28, 2027(1.1yr) | $96M |
| CRESEMBAN207500 | 3 | Mar 14, 2028(1.7yr) | $96M |
| ESBRIETN022535 | 19 | Sep 22, 2026(3mo) | $93M |
| NEUPRON021829 | 4 | Sep 1, 2027(1.2yr) | $93M |
| RUKOBIAN212950 | 2 | Nov 19, 2027(1.4yr) | $91M |
| PRISTIQN021992 | 1 | Jul 5, 2027(1.0yr) | $80M |
| JYNARQUEN204441 | 2 | Sep 1, 2026(2mo) | $76M |
| GILOTRIFN201292 | 5 | May 9, 2027(10mo) | $51M |
| NOURIANZN022075 | 2 | Sep 5, 2027(1.2yr) | $50M |
| CORLANORN206143 | 4 | Jun 12, 2027(11mo) | $47M |
| PROCYSBIN203389 | 12 | Mar 22, 2028(1.7yr) | $39M |
| TOVIAZN022030 | 3 | Dec 7, 2027(1.4yr) | $39M |
| EDARBIN200796 | 1 | Mar 26, 2028(1.7yr) | $37M |
| ALVESCON021658 | 1 | Feb 1, 2028(1.6yr) | $35M |
| HORIZANTN022399 | 3 | Nov 10, 2026(4mo) | $33M |
| TROKENDI XRN201635 | 10 | Nov 16, 2027(1.4yr) | $33M |
| OXTELLAR XRN202810 | 11 | Apr 13, 2027(9mo) | $31M |
| NAYZILAMN211321 | 4 | Jan 18, 2028(1.5yr) | $28M |
| EDARBYCLORN202331 | 3 | Mar 26, 2028(1.7yr) | $27M |
| EMPAVELIN215014 | 11 | May 14, 2028(1.9yr) | $25M |